This section is from the book "Isopathic / Homeopathic Materia Medica", by Konrad Werthmann. See also: Boericke's New Manual of Homeopathic Materia Medica with Repertory.
Mycobacteria and their fragments effect a strong stimulation of the T-cell system, inducing cellular defense reactions. This is primarily utilized therapeutically in tumor diseases, among others (J. Hartmann, Therapeutikon9, 1990).
Therapy with the preparation UTILIN "S" goes back historically to the application of a pathogen of the sea-turtle tuberculosis for the treatment of pulmonary tuberculosis by Professor Friedmann in the 1920s. Therefore, an outstanding immunotherapy became possible, which worked similarly to the officially sanctioned BCG inoculation, but without the occasional serious side effects. This preparation was further developed into an identically effective preparation of Mycobacterium phleifrom the special strain FU 36. In recent years, the immunostimulating properties of the cell-wall parts of the Mycobacteriumhave been intensively researched, whereby the equivalence of diverse mycobacterial species has been discovered. A focal point for therapy with BCG ( Mycobacterium bovis) in modern tumor treatment is presented in its instillation for cancer of the bladder. Here, also, the effectiveness of the Mycobacterium phleiFU 36 has proven itself as comparable.
In folk medicine, tea decoctions using hay, excrement from cows, or peat moss have long been used, without any knowledge of their containing Bacillus subtilisas active agent. Farmers in many countries utilized hay infusions for curing intestinal diseases in cattle.
As early as 1887, Metchnikoff described the growth-inhibiting effect of aerobic soil bacteria, particularly of Bacillus subtilis, in contrast to pathogens such as Streptococci, Staphylococci, Salmonellaand Mycobacterium tuberculosis.
Works by Ramon and Richou, as well as Jansen and Hirschmann showed in 1943/44 the antitoxic and antibiotic properties of that pathogen, which was generally referred to as "Hay bacillus".
However, the first reports about the oral, subcutaneous and intravenous application of Bacillus subtilisstrains were published in the years 1938/39 with outstanding therapeutic results. Particularly, its effectiveness with certain pseudo-tubercular forms was discovered at that time. The general stimulation effect on the nonspecific defensive capacity of the human organism already showed up in these beginnings of Subtilis Therapy. The name UTILIN has been used under trade mark protection for this new, special remedy since 1939. In later years, additional Bacillusstrains that are closely related to Bacillus subtilisfound their entry into the therapy under the terms of LATENSIN and RECARCIN.
Preparations with Bacillus species have manifold immunostimulating effects. Clinical studies yielded good success in recurring diseases of the urinary passages and the breathing organs in patients with defective immune situations in food allergies, as well as other chronic diseases that were brought about by a reduced immune status (J. Hartmann, Therapeutikon4, 1990).
The immunobiological preparations ARTHROKEHLAN "A" and ARTHROKEHLAN "U" were developed from the Siphonospora polymorphabacterial cultures of Dr. von Brehmer that were made into the preparations Toxinal and Arthrisinal.
Von Brehmer (1883-1958), a contemporary of Enderlein (1872-1968), originally devoted himself to virus research involving diseases of plants and animals. During the examination of an accidentally received human blood sample, he discovered also microorganisms that were partly moving and partly of immobile nature. He gave them the name of Siphonospora polymorpha. He was able to prove that even the smallest fluctuations of the blood pH value within the alkaline area effected the cyclogenetic upward development of the Siphonosporatoward their pathological stages. However, in acidic milieu, these higher stages fall apart again into their apathogenic, tiniest developmental stages. These works brought additional proof for Enderlein's publications on pleomorphism and the cyclogeny of the Endobionts released at the identical time.
Beginning 1935, von Brehmer researched an avirulent Siphonosporavaccine for therapeutic purposes. The first material was obtained from a gangrenous tooth pulp and root granuloma. From these sources, von Brehmer developed the preparation Toxinal, which was applied for rheumatic arthritic diseases, neuralgia and Herpes zoster, and Arthrisinal, a formol toxoid from highly active rod cultures, with its chief area of indication, the cancer diseases.
The original cultures of Dr. von Brehmer's Research Institute were later purified and identified, the Propionibacteriaand Corynebacteriaspecies were then isolated from them. These improved cultures are now forming the basis of the preparations ARTHROKEHLAN "A" and ARTHROKEHLAN "U".
An additional therapeutic development with Corynebacteriafollowed in the application of Corynebacterium parvumfor infection prophylaxis. This strain was later reclassified as Propionibacterium acnes. The activation of the monocyte-macrophage system is a general characteristic of the species Propionibacterium. Its antibacterial, antiviral, antiparasitic and antitumoral action are the result.
The latter, in particular, have been intensively examined in the strain Propionibacterium avidum. Its stimulatory effects on the hematopoietic system qualify it in the immune therapy especially in the treatment of myelosuppressive side effects of a cytostatic or radiation therapy.
The product series of SANUKEHL preparations (c.f. The Sanukehl Preparations - Polysaccharides for Haptenic Therapy) is based on a special production process, in which the polysaccharides of bacteria are extracted. These preparations are to be considered haptens, made of typical pathogenic Nosode germs, and defined as "antigen absorbers" (Cornelius). Their active principle is based on the binding of the pathogen antigens or pathogen toxins. The latter are commonly mobilized out of their body depots within a therapy with corresponding nosodes. In this way they effect a first reaction. However, persistent antigens can be a considerable obstruction for a nosode therapy. In such cases, the matching SANUKEHL preparation for each nosode is to be applied as middle agent, in order to restore the full nosode efficacy.
SANUKEHL Acne, Hapten from Propionibacterium acnes
SANUKEHL Brucel, Hapten from Brucella melitensis
SANUKEHL Cand, Hapten from Candida albicansof Serotypes A and B
SANUKEHL Coli, Hapten from Escherichia coli
SANUKEHL Klebs, Hapten from Klebsiella pneumoniae
SANUKEHL Myc, Hapten from Mycobacterium bovis
SANUKEHL Prot, Hapten from Proteus vulgaris
SANUKEHL Pseu, Hapten from Pseudomonas aeruginosa
SANUKEHL Salm, Hapten from Salmonella enteriditis
SANUKEHL Serra, Hapten from Serratia marcescens
SANUKEHL Staph, Hapten from Staphylococcus aureus
SANUKEHL Strep, Hapten from Streptococcus pyogenens
SANUKEHL Trich, Hapten from Trichophyton verrucosum